Optimi Health Completes First Export of Psilocybin to the United Kingdom for Phase 2 Clinical Trial
The shipment of naturally derived psilocybin, comprising both biomass and 5mg capsules, supports a planned Phase 2 clinical trial in the United Kingdom and was completed under export authorization from Health Canada and import authorization from the UK Home Office The shipment of naturally derived psilocybin, comprising both biomass and 5mg capsules, supports a planned Phase 2 clinical trial in the United Kingdom and was completed under export authorization from Health Canada and import authori
The shipment of naturally derived psilocybin, comprising both biomass and 5mg capsules, supports a planned Phase 2 clinical trial in the United Kingdom and was completed under export authorization from Health Canada and import authorization from the UK Home Office The shipment of naturally derived psilocybin, comprising both biomass and 5mg capsules, supports a planned Phase 2 clinical trial in the United Kingdom and was completed under export authorization from Health Canada and import authorization from the UK Home Office
Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.